Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Approval would help the company in its head-to-head market battle with main rival Novo Nordisk in the GLP-1 category, whose semaglutide is already approved for cardiovascular risk reduction in ...